DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR TANESPIMYCIN
» See Plans and Pricing
Clinical Trials for Tanespimycin
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT00003969 | Geldanamycin Analogue in Treating Patients With Advanced Cancer | Completed | Cancer Research UK | Phase 1 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of a geldanamycin analogue in treating patients with advanced cancer. |
| NCT00004065 | Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer | Completed | National Cancer Institute (NCI) | Phase 1 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of 17-N-allylamino-17-demethoxygeldanamycin in treating patients with refractory advanced solid tumors or hematologic cancers. |
| NCT00004065 | Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer | Completed | Memorial Sloan Kettering Cancer Center | Phase 1 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of 17-N-allylamino-17-demethoxygeldanamycin in treating patients with refractory advanced solid tumors or hematologic cancers. |
| NCT00004075 | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery | Completed | National Cancer Institute (NCI) | Phase 1 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of 17-N-allylamino-17-demethoxygeldanamycin in treating patients with solid tumors that cannot be removed by surgery. |
| NCT00004075 | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery | Completed | Mayo Clinic | Phase 1 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of 17-N-allylamino-17-demethoxygeldanamycin in treating patients with solid tumors that cannot be removed by surgery. |
| NCT00004241 | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma | Completed | National Cancer Institute (NCI) | Phase 1 | Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. This phase I trial is studying the side effects and best dose of 17-N-allylamino-17-demethoxygeldanamycin in treating patients with advanced epithelial cancer, malignant lymphoma, or sarcoma |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Tanespimycin
Condition Name
| Condition Name for | |
| Intervention | Trials |
| Unspecified Adult Solid Tumor, Protocol Specific | 12 |
| Recurrent Adult Diffuse Large Cell Lymphoma | 5 |
| Recurrent Mantle Cell Lymphoma | 5 |
| Recurrent Grade 3 Follicular Lymphoma | 5 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for Tanespimycin
Trials by Country
Clinical Trial Progress for Tanespimycin
Clinical Trial Phase
Clinical Trial Sponsors for Tanespimycin
Sponsor Name
